The SGLT2I dapagliflozin may decrease risk of peptic ulcer by lowering blood glucose and modulating ghrelin, motilin, and gastrin levels, thereby decreasing gastric acidity and inflammation while promoting mucosal healing [42]. Here, GHRL is linked to Peptic ulcer.